According to the latest data from the Hong Kong Stock Exchange, on January 26th, a shareholder of CUTIA-B (02487) transferred shares from Citibank to Morgan Stanley Hong Kong Securities. The transferred shares had a market value of HK$122 million, accounting for 7.07% of the holdings. Previously, CUTIA-B announced that its product CU-20101 (Botulinum Toxin Type A for Injection) achieved positive topline results in its Chinese Phase III clinical trial for improving moderate to severe glabellar lines.